AstraZeneca Stock Rating Upgraded by S&P Equity Research (AZN)
AstraZeneca (LON:AZN) was upgraded by S&P Equity Research to a “hold” rating in a research note issued on Friday, Analyst RN reports. The firm currently has a GBX 3,700 ($60.69) price target on the stock, up from their previous price target of GBX 2,900 ($47.56). S&P Equity Research’s price target suggests a potential upside of 3.53% from the stock’s previous close.
AstraZeneca (LON:AZN) traded up 2.38% on Friday, hitting GBX 3657.50. 1,931,292 shares of the company’s stock traded hands. AstraZeneca has a 52 week low of GBX 2895.00 and a 52 week high of GBX 3669.50. The stock’s 50-day moving average is GBX 3526. and its 200-day moving average is GBX 3301.12. The company’s market cap is £45.828 billion.
A number of other firms have also recently commented on AZN. Analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,640 ($59.70) price target on the stock. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,600 ($59.05) price target on the stock. Finally, analysts at Nordea Equity Research reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Tuesday. They now have a GBX 4,218.14 ($69.18) price target on the stock. Thirteen analysts have rated the stock with a sell rating, seventeen have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of GBX 3,144.46 ($51.57).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.